Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) was downgraded by equities researchers at StockNews.com from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Tuesday.
Several other equities research analysts also recently issued reports on the stock. Raymond James upgraded shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. Sidoti cut Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target for the company. in a report on Monday, December 9th. Royal Bank of Canada upped their price objective on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a "sector perform" rating in a report on Friday, March 21st. Canaccord Genuity Group boosted their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Finally, Oppenheimer upped their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a research note on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Prestige Consumer Healthcare presently has an average rating of "Hold" and an average target price of $93.33.
Read Our Latest Analysis on PBH
Prestige Consumer Healthcare Stock Performance
Shares of PBH stock traded up $1.46 during trading on Tuesday, reaching $82.17. 357,520 shares of the company's stock were exchanged, compared to its average volume of 284,137. Prestige Consumer Healthcare has a twelve month low of $62.35 and a twelve month high of $90.04. The firm's fifty day moving average price is $84.56 and its 200-day moving average price is $79.89. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $4.07 billion, a PE ratio of 19.24, a PEG ratio of 2.69 and a beta of 0.47.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. As a group, sell-side analysts anticipate that Prestige Consumer Healthcare will post 4.5 EPS for the current year.
Insider Buying and Selling
In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the sale, the senior vice president now directly owns 17,157 shares in the company, valued at $1,544,130. This represents a 8.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.60% of the stock is owned by company insiders.
Hedge Funds Weigh In On Prestige Consumer Healthcare
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Kestra Investment Management LLC bought a new position in Prestige Consumer Healthcare in the fourth quarter valued at approximately $27,000. CIBC Private Wealth Group LLC boosted its holdings in shares of Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock valued at $34,000 after purchasing an additional 152 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Prestige Consumer Healthcare in the 4th quarter valued at $40,000. McIlrath & Eck LLC raised its holdings in shares of Prestige Consumer Healthcare by 19.1% during the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after buying an additional 154 shares in the last quarter. Finally, Johnson Financial Group Inc. bought a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth $93,000. 99.95% of the stock is currently owned by institutional investors and hedge funds.
About Prestige Consumer Healthcare
(
Get Free Report)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Featured Articles
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
